Litigation Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)
✉ Email this page to a colleague
Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-01-13 |
| Court | District Court, D. Delaware | Date Terminated | 2022-04-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | LEK PHARMACEUTICALS D.D. | ||
| Patents | 7,566,729; 7,635,707; 7,696,236; 7,767,225; 7,767,700; 7,816,383; 7,910,610; 7,988,994; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,753,679; 8,754,109; 8,778,947 | ||
| Attorneys | Andy J. Miller | ||
| Firms | Greenberg Traurig, the Nemours Building | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Genentech, Inc. v. Sandoz, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Genentech, Inc. v. Sandoz, Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-01-13 | 1 | U.S. Patent No. 7,566,729 25. U.S. Patent No. 7,566,729 (“the ‘729 patent”), entitled… U.S. Patent No. 7,767,700 29. U.S. Patent No. 7,767,700 (“the ‘700 patent”), entitled… U.S. Patent No. 8,013,002 35. U.S. Patent No. 8,013,002 (“the ‘002 patent”), entitled… U.S. Patent No. 8,383,150 41. U.S. Patent No. 8,383,150 (“the ‘150 patent”), entitled… U.S. Patent No. 8,609,701 47. U.S. Patent No. 8,609,701 (“the ‘701 patent”), entitled | External link to document | |
| 2020-10-01 | 183 | Notice to Take Deposition | O. The “ ‘729 patent” refers to U.S. Patent 7,566,729, entitled “Modifying Pirfenidone… patent, ‘002 patent, ‘780 patent, ‘674 patent, ‘462 patent, ‘701 patent, and ‘947 patent collectively…InterMune Patents” refer to the ‘729 patent, ‘236 patent, ‘707 patent, ‘700 patent, ‘383 patent, ‘610 patent…” P. The “ ‘236 patent” refers to U.S. Patent 7,696,236, entitled “Method of Providing…” Q. The “ ‘707 patent” refers to U.S. Patent 7,635,707, entitled “Modifying Pirfenidone | External link to document |
| 2020-10-20 | 226 | Order - -Memorandum and Order | single term in U.S. Patent Nos. 7,566,729 (“the ’729 patent”), 7,635,707 (“the ’707 patent”), and 8,592,462… construction for a single term in U.S. Patent Nos. 7,566,729, 7,635,707, and 8,592,462. Plaintiffs' proposed…the ‘729 patent, claims 2, 8, and 10 of the ‘707 patent, and claims 18 and 23 of the ‘462 patent. (D.I. … “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification | External link to document |
| 2019-01-13 | 3 | 12/18/2027 8,420,674 12/18/2027 7,566,729 4/22/2029 7,635,707 4/22/2029…of 2 PageID #: 348 Asserted Patents and Expiration Dates: Patent No. Expiration 7,767,225… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 12/3/2018. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 4/15/… ) SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG | External link to document | |
| 2021-11-02 | 354 | Redacted Document | obsessive compulsive disorder. See U.S. Patent Nos. 7,816,383, claim 6; 8,103,002, claims 3 and 9. To …infringement issues being litigated. One family of patents Plaintiffs assert claims methods of managing pirfenidone…January 2019 19 April 2022 1:19-cv-00078 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-03-22 | 386 | Opinion | . 7,566,729 ("the ' 729 patent") (JTX000l), (ii) claims 6 and 14 of U.S. Patent No. 7,635…the LFT patents are invalid as obvious but did not prove the Asserted Claims of the DDI patents are invalid…infringed several of its patents. (D.I. 1). Plaintiffs asserted six patents at the bench trial, which…six patents directed toward treatment methods involving pirfenidone: (i) claim 9 of U.S. Patent No. …quot;the ' 707 patent") (JTX0002), (iii) claims 12 and 28 of U.S. Patent No. 8,592,462 (" | External link to document |
| 2019-01-13 | 4 | B2; 7,696,236 B2; 7,767,700 B2; 8,420,674 B2; 7,566,729 B1; 7,635,707 B1; 8,592,462 B2; 8,609,701 B2; … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,767,225 B2; …January 2019 19 April 2022 1:19-cv-00078 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
